Pfizer (PFE) said Saturday that its investigational drug sasanlimab in combination with standard of care Bacillus Calmette-Guerin as induction and maintenance therapy in patients with high-risk non-muscle invasive bladder cancer met its primary endpoint of event-free survival in a phase 3 trial.
The trial showed a 32% reduction in the risk of disease-related events with the sasanlimab combination regimen as compared with the standard of care treatment alone, the pharmaceutircal giant said.
The probability of being event-free at 36 months was 82.1% with sasanlimab in combination with BCG and 74.8% with BCG alone, the company said.
Sasanlimab in combination with induction-only BCG failed to meet a secondary endpoint of prolongation of event-free survival compared with BCG alone as an induction and maintenance therapy, the company said.
Pfizer said it has shared study data with health authorities worldwide to support potential regulatory filings.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。